Safety and Efficacy of Oseltamivir in Children Younger Than One Year of Age

National Institute of Allergy and Infectious Diseases (NIAID)

Status and phase

Withdrawn

Phase 2

Conditions

Influenza

Treatments

Drug: Oseltamivir

Study type

Interventional

Funder types

NIH

Identifiers

NCT01037634

SEA 022

Details and patient eligibility

About

Currently, there is no standard treatment for influenza with related lower respiratory tract infection (LRTI) in children younger than one year of age, even though influenza related LRTI is a potentially fatal illness in these children. This study will test a medicine for influenza in children younger than one year of age to see if it is safe and effective.

Full description

Influenza-related lower respiratory tract infection (LRTI) can cause serious illness or death in children younger than a year old. Only four medications are registered to treat influenza, and these do not have detailed recommendations for treating children younger than one year of age. One of these medications, oseltamivir, has no official recommendation for usage in children younger than one year of age, but it may be the best treatment for certain strains of influenza. A small number of children younger than one year of age have received oseltamivir in several countries with good clinical outcomes and apparently good tolerability. This study will test oseltamivir in children younger than one year of age to see if it is safe and effective.

Children younger than one year of age with influenza will be recruited for this study. Participants will receive the usual care for influenza with the addition of oseltamivir. Oseltamivir will be given orally for 5 days to children with human influenza, 7 days to children with H1N1 influenza in Vietnam, and 10 days to children with avian influenza. Participants will need to remain in the hospital between 5 and 12 days, depending on their illnesses.

Study assessments will be performed daily for 14 days with follow-up examinations occurring 1 to 2 weeks, 6 months, and 12 months after study entry. These assessments will include normal tests for children with influenza, such as blood tests and chest x-rays, but additional blood and nose, throat, and mouth samples will be collected for the study. Participants on a breathing machine will give lung samples.

Sex

All

Ages

1 to 12 months old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

Informed consent signed by a parent or legal guardian
Younger than 12 months of age when first seen with a lower respiratory tract infection (LRTI)
LRTI must be moderate or severe and influenza must be virologically proven by a respiratory specimen
History of fever within 14 days prior to presentation (although fever at presentation is not required) plus any two of the following: cough, difficulty breathing or shortness of breath, increased respiratory rate for current age, intercostal recession, use of accessory muscles, nasal flare or grunting, crepitations with or without wheezing, a consistent abnormal chest x-ray (e.g., new infiltrate, hyperinflation)
Virological evidence of influenza on any one of the tests specified in the protocol

Exclusion Criteria for Children with Non-Avian Influenza:

Known allergy to oseltamivir

Additional Exclusion Criteria for Children with Non-Avian Influenza:

Illness duration greater than 14 days on the day of hospital admission
Creatinine clearance less than 10 mL/min/1.73m2, including a requirement for dialysis or hemofiltration